QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ef-hutton-maintains-buy-on-annovis-bio-maintains-21-price-target

EF Hutton analyst Jason Kolbert maintains Annovis Bio (NYSE:ANVS) with a Buy and maintains $21 price target.

 hc-wainwright--co-reiterates-buy-on-annovis-bio-maintains-30-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $30 price tar...

 ef-hutton-initiates-coverage-on-annovis-bio-with-buy-rating-announces-price-target-of-21

EF Hutton analyst Jason Kolbert initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target o...

 annovis-bio-secures-us-patent-for-treatment-of-acute-traumatic-brain-injury-with-buntanetap

Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneeri...

 hc-wainwright--co-reiterates-buy-on-annovis-bio-maintains-30-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $30 price tar...

 hc-wainwright--co-maintains-buy-on-annovis-bio-raises-price-target-to-30

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and raises the price target ...

 annovis-bio-shares-resume-trade
Annovis Bio Shares Resume Trade
07/09/2024 13:39:59

 why-nio-shares-are-trading-lower-by-over-8-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has res...

 whats-going-on-with-annovis-shares-today

Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognit...

 tesla-paramount-global-annovis-bio-eli-lilly-amazon-why-these-5-stocks-are-on-investors-radars-today

On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in p...

 rodman--renshaw-reiterates-buy-on-annovis-bio-maintains-67-price-target

Rodman & Renshaw analyst Elemer Piros reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $67 price target.

 whats-going-with-annovis-bio-shares-tuesday

Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson'...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION